Genomic and transcriptomic determinants of clinical outcomes in patients with AML and DNMT3A mutations www.nature.com/articles/s41...

Ph-Positive Acute Lymphoblastic Leukemia — 25 Years of Progress | New England Journal of Medicine www.nejm.org/doi/full/10....

The evolving landscape of epigenetic target molecules and therapies in myeloid cancers www.nature.com/articles/s41...

How I treat postimmunotherapy relapsed B-ALL ashpublications.org/blood/articl...

Measurable residual disease monitoring in AML with FLT3-ITD treated with intensive chemotherapy plus midostaurin | Blood Advances | American Society of Hematology ashpublications.org/bloodadvance...

How insurance companies degrade the patient-doctor relationship, by Helen Ouyang, my friend and exceptional physician-author gift link www.nytimes.com/2024/12/08/o... @nytopinion.nytimes.com

#myeloMATCH is the NCI’s #precisionmedicine trial in #myeloid cancer: advanced biomarker testing in newly diagnosed acute myeloid #leukemia (#AML) or #myelodysplastic syndrome (#MDS) & treatment substudies by the Alliance, Canadian Cancer Trials Group, @eaonc.bsky.social & SWOG. swog.org/myeloMATCH

Relevance of blast counts for genetic subclassification in MDS www.nature.com/articles/s41...

8 days ago, ASH decided to join Bluesky. 🌤️ So far, we're enjoying fewer distractions & more meaningful connections. 💬 Engaging with our amazing #hematology and #hemeonc communities has never been easier. We created an #ASH24 feed for you & we have more feeds coming soon: bit.ly/ASH24feed #Hemesky

Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine ashpublications.org/blood/articl...

Venetoclax + HMA for previously untreated Higher-Risk Myelodysplastic Syndromes and genotype signatures onlinelibrary.wiley.com/doi/full/10....

👇👇👇 Genetic risk stratification and outcomes in treatment-naive AML treated with venetoclax + azacitidine ashpublications.org/blood/articl...

It’s always a great start to the day to learn we have one more drug to offer patients with r/r leukemia! 🎗️🩸💊 www.fda.gov/drugs/resour...

Very interesting 👇👇

Not many papers change the way I think about AML, but this exceptional work shows how cell states and genetics intertwine to mediate venetoclax resistance, unifying previous studies by identifying RAS-mutated LSCs that are primed to produce myeloid cells #hemesky 🩸🧪 www.nature.com/articles/s41...

New to Bluesky 🦋 Hello to all!